Innoviva, Inc. (INVA)
20.97
+0.20
(+0.96%)
USD |
NASDAQ |
Sep 01, 13:06
Innoviva Free Cash Flow : 189.44M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 189.44M |
| March 31, 2026 | 181.97M |
| December 31, 2025 | 195.80M |
| September 30, 2025 | 196.54M |
| June 30, 2025 | 196.34M |
| March 31, 2025 | 195.99M |
| December 31, 2024 | 184.42M |
| September 30, 2024 | 162.29M |
| June 30, 2024 | 157.58M |
| March 31, 2024 | 152.05M |
| December 31, 2023 | 140.65M |
| September 30, 2023 | 116.41M |
| June 30, 2023 | 88.38M |
| March 31, 2023 | 129.22M |
| December 31, 2022 | 201.66M |
| September 30, 2022 | 291.18M |
| June 30, 2022 | 372.21M |
| March 31, 2022 | 377.80M |
| December 31, 2021 | 363.81M |
| September 30, 2021 | 350.71M |
| June 30, 2021 | 328.56M |
| March 31, 2021 | 323.74M |
| December 31, 2020 | 313.10M |
| September 30, 2020 | 294.71M |
| June 30, 2020 | 277.56M |
| Date | Value |
|---|---|
| March 31, 2020 | 254.26M |
| December 31, 2019 | 257.45M |
| September 30, 2019 | 252.33M |
| June 30, 2019 | 255.04M |
| March 31, 2019 | 250.27M |
| December 31, 2018 | 223.53M |
| September 30, 2018 | 209.61M |
| June 30, 2018 | 192.99M |
| March 31, 2018 | 163.90M |
| December 31, 2017 | 141.75M |
| September 30, 2017 | 114.95M |
| June 30, 2017 | 91.40M |
| March 31, 2017 | 81.22M |
| December 31, 2016 | 60.71M |
| September 30, 2016 | 46.56M |
| June 30, 2016 | 29.27M |
| March 31, 2016 | 19.00M |
| December 31, 2015 | 10.12M |
| September 30, 2015 | -11.54M |
| June 30, 2015 | -60.26M |
| March 31, 2015 | -160.78M |
| December 31, 2014 | -266.41M |
| September 30, 2014 | -337.71M |
| June 30, 2014 | -343.19M |
| March 31, 2014 | -262.22M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Zevra Therapeutics, Inc. | 32.62M |
| Collegium Pharmaceutical, Inc. | 328.28M |
| CorMedix, Inc. | 250.11M |
| ANI Pharmaceuticals, Inc. | 167.52M |
| Corcept Therapeutics, Inc. | 106.92M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 51.97M |
| Cash from Investing (Quarterly) | -55.26M |
| Cash from Financing (Quarterly) | -29.40M |
| Free Cash Flow Per Share (Quarterly) | 0.702 |
| Free Cash Flow to Equity (Quarterly) | 108.61M |
| Free Cash Flow to Firm (Quarterly) | 55.77M |
| Free Cash Flow Yield | 11.00% |